Business

3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted

3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted

3d Medicines, Inc.January 9, 20265
3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted

About this update from 3d Medicines, Inc.

3D Medicines Inc HKEX:1244:NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NMPA

View stock analysis, news, and events for 3d Medicines, Inc.